IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This analysis from the PARTNER 3 trial was presented during the […]
Other News
CryoLife Reports Third Quarter 2021 Financial Results
ATLANTA, Nov. 4, 2021 /PRNewswire/ — Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in […]
iRhythm Technologies Announces Third Quarter 2021 Financial Results
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended September 30, 2021. Third Quarter 2021 Financial Highlights Revenue was $85.4 million, a 18.7% increase […]
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated […]
Acceleron Reports Third Quarter 2021 Financial Results
– Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) – – Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition scheduled for December 11 to […]
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT™ on Isolated Systolic Hypertension and Pulse Pressure
November 05, 2021 08:00 ET | Source: Orchestra BioMed BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation. Patients with Isolated Systolic Hypertension (ISH) treated with BackBeat CNT experienced clinically meaningful and statistically significant reductions of 7.4 mmHg in ambulatory systolic […]
NEW DATA DEMONSTRATES SAFETY AND PERFORMANCE OF CONTINUOUS ASPIRATION THROMBECTOMY WITH PENUMBRA’S INDIGO® SYSTEM CAT™ RX CATHETER IN HIGH-RISK PATIENTS WITH ACUTE CORONARY SYNDROME
CAT RX established high rates of blood clot removal, blood flow restoration and myocardial perfusion normalization No serious adverse events associated with the use of sustained power aspiration Results of the CHEETAH clinical study were presented at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) conference ALAMEDA, Calif. – November 5, 2021 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced that the CHEETAH clinical study of its Indigo® System CATTM RX Catheter successfully met the primary endpoint and […]
Stamford Health Forges New Relationship with Columbia University Irving Medical Center to Expand World-Class Heart Surgery Capabilities
STAMFORD, CT/ NOVEMBER 3, 2021— Stamford Health, known for its award-winning cardiac care through the Heart & Vascular Institute, has expanded its relationship with Columbia University to offer treatment and expertise from Columbia University Irving Medical Center’s nationally recognized heart surgeons. As a result of this new relationship, five of […]
Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu […]
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
TEL AVIV, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that […]
Recent
UBC MOSAIC and LifeLabs Unlock New Ways to Manage and Predict Heart Health
Ruixiang Silicone Releases Platinum-Cured Medical Silicone Tubing for Cardiac, Infusion, and Hemodialysis Device Manufacturers
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions
Popular
- No commented posts yet